REACH-ASD: A UK randomised controlled trial of a new post-diagnostic psycho-education and acceptance and commitment therapy programme against treatment-as-usual for improving the mental health and adjustment of caregivers of children recently diagnosed with Autism Spectrum Disorder
Autor: | Kathy Leadbitter, Richard Smallman, Kirsty James, Gemma Shields, Ceri Ellis, Sophie Langhorne, Louisa Harrison, Latha Hackett, Alison Dunkerley, Leo Kroll, Linda Davies, Richard Emsley, Penny Bee, Jonathan Green, REACH-ASD Team |
---|---|
Rok vydání: | 2022 |
Předmět: |
Randomised controlled trial
Autism Spectrum Disorder/diagnosis Autism Spectrum Disorder Autism Cost-Benefit Analysis Medicine (miscellaneous) United Kingdom Caregivers/psychology Mental Health Caregivers Diagnosis Quality of Life Humans Pharmacology (medical) Acceptance and Commitment Therapy Child Psycho-education |
Zdroj: | Leadbitter, K, Smallman, R, James, K, Shields, G, Ellis, C, Langhorne, S, Harrison, L, Hackett, L, Dunkerley, A, Kroll, L, Emsley, R, Bee, P, Green, J & REACH-ASD Team 2022, ' REACH-ASD : a UK randomised controlled trial of a new post-diagnostic psycho-education and acceptance and commitment therapy programme against treatment-as-usual for improving the mental health and adjustment of caregivers of children recently diagnosed with autism spectrum disorder ', Trials, vol. 23, no. 1, 585 . https://doi.org/10.1186/s13063-022-06524-1 2022, ' REACH-ASD : a UK randomised controlled trial of a new post-diagnostic psycho-education and acceptance and commitment therapy programme against treatment-as-usual for improving the mental health and adjustment of caregivers of children recently diagnosed with autism spectrum disorder ', Trials, vol. 23, no. 1, 585 . https://doi.org/10.1186/s13063-022-06524-1 |
DOI: | 10.21203/rs.3.rs-1534337/v1 |
Popis: | Background Autism is a neurodevelopmental disability affecting over 1% of UK children. The period following a child’s autism diagnosis can present real challenges in adaptation for families. Twenty to 50% of caregivers show clinically significant levels of mental health need within the post-diagnostic period and on an ongoing basis. Best practice guidelines recommend timely post-diagnostic family support. Current provision is patchy, largely unevidenced, and a source of dissatisfaction for both families and professionals. There is a pressing need for an evidenced programme of post-diagnostic support focusing on caregiver mental health and adjustment, alongside autism psycho-education. This trial tests the clinical and cost-effectiveness of a new brief manualised psychosocial intervention designed to address this gap. Methods This is a multi-centre two-parallel-group single (researcher)-blinded randomised controlled trial of the Empower-Autism programme plus treatment-as-usual versus usual local post-diagnostic offer plus treatment-as-usual. Caregivers of children aged 2–15 years with a recent autism diagnosis will be recruited from North West England NHS or local authority centres. Randomisation is individually by child, with one “index” caregiver per child, stratified by centre, using 2:1 randomisation ratio to assist recruitment and timely intervention. Empower-Autism is a group-based, manualised, post-diagnostic programme that combines autism psycho-education and psychotherapeutic components based on Acceptance and Commitment Therapy to support caregiver mental health, stress management and adjustment to their child’s diagnosis. The comparator is any usual local group-based post-diagnostic psycho-education offer. Receipt of services will be specified through health economic data. Primary outcome: caregiver mental health (General Health Questionnaire-30) at 52-week follow-up. Secondary outcomes: key caregiver measures (wellbeing, self-efficacy, adjustment, autism knowledge) at 12-, 26- and 52-week follow-up and family and child outcomes (wellbeing and functioning) at 52-week endpoint. Sample: N=380 (approximately 253 intervention/127 treatment-as-usual). Primary analysis will follow intention-to-treat principles using linear mixed models with random intercepts for group membership and repeated measures. Cost-effectiveness acceptability analyses will be over 52 weeks, with decision modelling to extrapolate to longer time periods. Discussion If effective, this new approach will fill a key gap in the provision of evidence-based care pathways for autistic children and their families. Trial registration ISRCTN 45412843. Prospectively registered on 11 September 2019. |
Databáze: | OpenAIRE |
Externí odkaz: |